Status:
NOT_YET_RECRUITING
Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Lead Sponsor:
Dhaka Medical College
Conditions:
Hemophilia A
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
Low dose factor VIII prophylaxis is practiced around the world. Role of standard dose Emicizumab prophylaxis is well established. Emicizumab is an expensive drug. Standard dose Emicizumab prophylaxis ...
Detailed Description
Selection criteria for the study- Severe hemophilia A patients with or without inhibitor to factor VIII will be eligible to participate in the study. Patients with inhibitor will not be included in fa...
Eligibility Criteria
Inclusion
- Severe hemophilia A patient with or without inhibitor to factor VIII.
Exclusion
- 1\. Severe hemophilia A patient not willing to participate.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06938659
Start Date
June 1 2025
End Date
July 31 2026
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dhaka Medical College Hospital
Dhaka, Bangladesh, 1000